Twist Bioscience (NASDAQ:TWST) SVP Paula Green Sells 1,007 Shares of Company Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 1,007 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total value of $136,347.80. Following the sale, the senior vice president directly owned 105,625 shares in the company, valued at approximately $14,301,625. The trade was a 0.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paula Green also recently made the following trade(s):

• On Friday, October 2nd, Paula Green sold 10,088 shares of Twist Bioscience stock. The shares were sold at an average price of $188.88, for a total value of $1,905,421.44.
• On Monday, September 21st, Paula Green sold 294 shares of Twist Bioscience stock. The stock was sold at an average price of $165.49, for a total transaction of $48,654.06.

Twist Bioscience Stock Performance

TWST stock opened at $120.61 on Friday. The firm has a market cap of $7.56 billion, a price-to-earnings ratio of -54.33 and a beta of 2.25. The firm has a 50-day simple moving average of $152.00 and a two-hundred day simple moving average of $90.68. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $219.71. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The firm had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.33 EPS. On average, equities analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Key Stories Impacting Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist Bioscience has launched MRD Express, a development that could support its presence in the minimal residual disease testing market. The article also notes the stock is entering earnings week, when investors may look for updates on the product and business outlook. Read More.
• Neutral Sentiment: A separate analysis describes an “undervalued” investment narrative but flags the company’s sales valuation as expensive, presenting a mixed view rather than a clear near-term catalyst. Read More.
• Neutral Sentiment: Four executives and insiders, including CEO Emily M. Leproust, sold a combined 6,677 shares at $135.40. The transactions were reported as covering tax withholding obligations related to equity-award vesting, which makes them less indicative of discretionary selling.
• Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The available headline does not detail the report’s claims, but the coverage appears to have weighed on investor sentiment. Read More.

Institutional Trading of Twist Bioscience

Several large investors have recently bought and sold shares of TWST. Abacus Wealth Partners LLC boosted its position in Twist Bioscience by 4.3% in the third quarter. Abacus Wealth Partners LLC now owns 2,332 shares of the company’s stock valued at $451,000 after buying an additional 96 shares during the last quarter. Root Financial Partners LLC purchased a new position in Twist Bioscience during the 3rd quarter worth approximately $33,000. GAMMA Investing LLC raised its position in Twist Bioscience by 24.4% during the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock worth $97,000 after buying an additional 185 shares during the last quarter. Abel Hall LLC lifted its stake in Twist Bioscience by 3.6% during the 3rd quarter. Abel Hall LLC now owns 5,514 shares of the company’s stock valued at $1,066,000 after acquiring an additional 191 shares during the period. Finally, Allworth Financial LP lifted its stake in Twist Bioscience by 54.9% during the 2nd quarter. Allworth Financial LP now owns 601 shares of the company’s stock valued at $62,000 after acquiring an additional 213 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on TWST shares. Canaccord Genuity Group upped their price target on Twist Bioscience from $120.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. TD Cowen raised their price objective on Twist Bioscience from $115.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Jefferies Financial Group started coverage on Twist Bioscience in a research note on Thursday, October 8th. They set a “hold” rating and a $150.00 target price on the stock. Barclays upped their target price on Twist Bioscience from $112.00 to $215.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Finally, BWS Financial reaffirmed a “sell” rating and set a $45.00 target price on shares of Twist Bioscience in a research report on Friday, September 18th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Twist Bioscience presently has an average rating of “Hold” and a consensus target price of $153.00.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.